Clinical trialPhase 2
NCT04867616. Bepranemab (UCB0107) in prodromal to mild Alzheimer's disease
NCT04867616
Completed phase 2 trial sponsored by UCB Biopharma SRL. Primary completion 24 May 2024. The Lancet Neurology report (PMID 43008775) says the CDR-SB primary endpoint was not met.
1 news item
News about this trialScales
Identifiers
- NCT
- NCT04867616
Original sources
Details
- Phase
- Phase 2
- Status
- Completed
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.